Composition for improving membrane composition and functioning of cells

Patent metadata

Field	Value
Publication number	US-9463176-B2
Application number	US-201113294587-A
Country	US
Kind code	B2
Filing date	Nov 11, 2011
Priority date	Dec 23, 2005
Publication date	Oct 11, 2016
Grant date	Oct 11, 2016

Abstract

It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises
a) a lipid fraction comprising at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdenum,

the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.

First claim

The invention claimed is:

1. A composition comprising a lipid fraction having at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), a nucleotide fraction, a protein fraction including cysteine, a phospholipid, a vitamin, and a mineral fraction including manganese or molybdenum, wherein the lipid fraction comprises an ω-6 polyunsaturated fatty acid having 18 or more carbon atoms in an amount of 8-30 wt % of the fatty acids.

2. A composition comprising a lipid fraction having at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), a nucleotide fraction, a protein fraction including cysteine, a phospholipid, a vitamin, and a mineral fraction including manganese or molybdenum, wherein the lipid fraction comprises more than 0.01 wt % of at least one of glycolipids, gangliosides, sulfatides or sphingomyelin.

3. The composition according to claim 1 , wherein the nucleotide fraction includes nucleotides or nucleosides.

4. The composition according to claim 1 , further comprising a digestible carbohydrate fraction providing a source of galactose or ribose.

5. The composition according to claim 1 , wherein the lipid fraction includes a lipid from a dairy product, from eggs or from the endosperm of plant seeds or beans.

6. The composition according to claim 1 , wherein the lipid fraction comprises fat globules having a size of 0.001-10 μm.

7. A composition comprising a lipid fraction having at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), a nucleotide fraction, a protein fraction including cysteine, a phospholipid, a vitamin, and a mineral fraction including manganese or molybdenum, wherein the lipid comprises 1.3-16 wt % phospholipids or 0.1-20 wt % glycoproteins and glycolipids.

8. A composition comprising a lipid fraction having at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), a nucleotide fraction, a protein fraction including cysteine, a phospholipid, a vitamin, and a mineral fraction including manganese or molybdenum, wherein the protein fraction has a weight ratio of aspartate to glutamate of at least 0.42.

9. A composition comprising a lipid fraction having at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), a nucleotide fraction, a protein fraction including cysteine, a phospholipid, a vitamin, and a mineral fraction including manganese or molybdenum, having an energy content of 50-120 kcal, a protein content of 1-10 g, a lipids content of lipids 1-5 g, and a content of digestible carbohydrates of 4-20 g, and further comprising:
a) at least one of DHA, DPA or EPA in a sum amount of 400-3300 mg
b) 30-280 mg cysteine
c) 100-1000 mg phospholipids
d) 0.5-3 mg vitamin B6
e) 50-500 ug folic acid
f) 1-30 ug vitamin B12, and
g) 0.07-2 mg manganese.

10. The composition according to claim 1 wherein the nucleotide is a monophosphate.

11. The composition according to claim 1 wherein the nucleotide is uridine monophosphate.

12. The composition according to claim 3 wherein the nucleoside is adenosine or guanosine.

13. The composition according to claim 2 wherein the nucleotide is a monophosphate.

14. The composition according to claim 2 wherein the nucleotide is uridine monophosphate.

15. The composition according to claim 7 wherein the nucleotide is a monophosphate.

16. The composition according to claim 7 wherein the nucleotide is uridine monophosphate.

17. The composition according to claim 8 wherein the nucleotide is a monophosphate.

18. The composition according to claim 8 wherein the nucleotide is uridine monophosphate.

19. The composition according to claim 9 wherein the nucleotide is a monophosphate.

20. The composition according to claim 9 wherein the nucleotide is uridine monophosphate.

Assignees

• Hageman Robert J J
• Nutricia Nv

Inventors

• Hageman Robert J J

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title